The Intrahepatic Cholangiocarcinoma Market is driven by Rising Incidence of Cancer
Intrahepatic cholangiocarcinoma is a rare form of primary liver cancer that originates in the epithelial cells lining of the intrahepatic bile ducts inside the liver. It commonly occurs in patients with conditions that damage these bile ducts such as primary sclerosing cholangitis (PSC). Treatment options for intrahepatic cholangiocarcinoma (ICC) include surgical resection, liver transplantation, chemotherapy, radiation therapy, and liver transplantation.
The global Intrahepatic Cholangiocarcinoma market is estimated to be valued at US $250 million in 2027 and is expected to exhibit a CAGR of 8.5% over the forecast period between 2020 and 2027.
Key Takeaways
Key players operating in the Intrahepatic Cholangiocarcinoma are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Sanofi, Bayer AG, Celgene Corporation, Bristol-Myers Squibb, Pfizer, Inc., Concordia Healthcare.
Rising incidence of cancer and high rate of mortality associated with Intrahepatic Cholangiocarcinoma, novel therapies and early diagnosis are expected to boost the market growth. Growing demand for effective targeted therapies and combination therapies with immunotherapy will further augment the market Intrahepatic Cholangiocarcinoma Market Growth. Increasing R&D investments, clinical trials and approval of new drugs for treatment will accelerate the global expansion of Intrahepatic Cholangiocarcinoma market.
The ey driver influencing the growth of Intrahepatic Cholangiocarcinoma market is the rising incidence rate of cancer. The increasing prevalence of primary sclerosing cholangitis (PSC) which is one of the major risk factor for Intrahepatic Cholangiocarcinoma has resulted in spurring the market growth. According to statistics, PSC affects approximately 10 to 20 individuals per million in the U.S. and Europe every year. Moreover, aging population and changing lifestyle have also contributed to the rising prevalence of cancer which drives the demand for effective therapeutics and aids the market growth.
Geopolitical Impact on Intrahepatic Cholangiocarcinoma Market Growth
The global geopolitical landscape is experiencing heightened tensions and uncertainties which is impacting the intrahepatic cholangiocarcinoma market as well. The rising geostrategic competition and political risks have made companies wary about long term investments and expansion plans. Fast changing trade policies and sanctions on key markets are hindering seamless supply chain and clinical trials. Furthermore, budget allocation for health care is facing cuts in many economies amid defense spending priorities. This has negatively impacted R&D investments into rare cancer drugs and devices.
Intrahepatic Cholangiocarcinoma Market - https://www.coherentmi.com/ind....ustry-reports/intrah
